Prime Medicine, Inc. (PRME) Revenue History
Annual and quarterly revenue from 2019 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2024)
PRME's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
PRME Revenue Analysis (2019–2024)
As of February 28, 2026, Prime Medicine, Inc. (PRME) generated trailing twelve-month (TTM) revenue of $6.0 million, reflecting explosive growth of +486.1% year-over-year. The most recent quarter (Q3 2025) recorded $1.2 million in revenue, up 9.9% sequentially.
Looking at the longer-term picture, PRME's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $5.2 million in 2020.
Revenue diversification analysis shows PRME's business is primarily driven by Reportable Segment (100%). With over half of revenue concentrated in Reportable Segment, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including ALNY (+65.2% YoY), IONS (+33.8% YoY), and ARWR (+4081.8% YoY), PRME has underperformed the peer group in terms of revenue growth. Compare PRME vs ALNY →
Peer Comparison
Compare PRME's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| PRMECurrent | $6M | +486.1% | - | -6787.4% | |
| ALNY | $3.7B | +65.2% | +49.8% | 13.5% | |
| IONS | $944M | +33.8% | +5.3% | -40.5% | |
| ARWR | $829M | +4081.8% | +56.6% | 11.9% | |
| CRSP | $4M | -81.7% | +37.3% | -18933.6% | |
| BEAM | $140M | +120.0% | +466.3% | -274.6% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $3.0M | - | $3.0M | 100.0% | $-202,467,000 | -6787.4% |
| 2023 | $0 | - | $0 | - | $-204,792,000 | - |
| 2022 | $0 | - | $0 | - | $-116,544,000 | - |
| 2021 | $0 | -100.0% | $0 | - | $-84,474,000 | - |
| 2020 | $5.2M | - | $2.2M | 42.8% | $-932,000 | -17.9% |
| 2019 | $0 | - | $-2,760,000 | - | $-2,172,000 | - |
See PRME's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PRME Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare PRME vs AGIO
See how PRME stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is PRME's revenue growth accelerating or slowing?
PRME revenue is accelerating at +486.1% year-over-year, exceeding the 5-year CAGR of N/A. TTM revenue reached $6M. Growth momentum has increased versus prior periods.
What is PRME's long-term revenue growth rate?
Prime Medicine, Inc.'s 5-year revenue CAGR of N/A reflects the sustained expansion pattern. Current YoY growth of +486.1% is above this long-term average.
How is PRME's revenue distributed by segment?
PRME reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2019-2024 are available for download. Segment mix reveals concentration and diversification trends.